1W Return
1M Return
6M Return
1Y Return
3Y Return
Start SIP in Vanta Bioscience
Vanta Bioscience Stock Performance
52 Week Low - High
Today’s Low - High
Open
Prev. Close
Total Traded Value
Vanta Bioscience Fundamental
Market Cap (in crs)
Face Value
Turnover (in lacs)
Key Metrics
Qtr Change %
72.41% Fall from 52W High
-38.9
Dividend yield 1yr %
0
Vanta Bioscience Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
Current Price
5Day EMA
21.90
10Day EMA
22.40
12Day EMA
22.60
20Day EMA
23.90
26Day EMA
25.00
50Day EMA
29.00
100Day EMA
35.50
200Day EMA
45.00
5Day SMA
22.60
10Day SMA
21.90
20Day SMA
23.50
30Day SMA
25.80
50Day SMA
29.70
100Day SMA
36.80
150Day SMA
41.90
200Day SMA
49.00
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 750 Rs | 750 Rs |
Week Rs | 1500 Rs | 1500 Rs |
Month Rs | null Rs | null Rs |
Resistance & Support
20.76
Pivot
Resistance
First Resistance
20.76
Second Resistance
20.76
Third Resistance
20.76
Support
First Support
20.76
Second support
20.76
Third Support
20.76
Relative Strength Index
33.86
Money Flow Index
4.04
MACD
-2.36
MACD Signal
-2.67
Average True Range
1.46
Average Directional Index
34.19
Rate of Change (21)
-32.49
Rate of Change (125)
-62.89
Similar stocks
Similar Stocks
Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
13.10 | 19.7 | 75.24 | 21.85 | -9.70% | -6.15% | -54.31% | -70.11% | -80.65% | 0.00% | 0.00 | 58.06 | 0.66 | ||
Family Care Hospitals Ltd. | 4.71 | - | - | - | - | - | - | - | - | - | - | - | - | |
Boston Bio Systems Ltd. | 8.70 | - | - | - | - | - | - | - | - | - | - | - | - | |
Sharma East India Hospitals & Medical Research Ltd. | 75.62 | - | - | - | - | - | - | - | - | - | - | - | - | |
Dr. Lalchandani Labs Ltd. | 11.42 | - | - | - | - | - | - | - | - | - | - | - | - | |
Gian Life Care Ltd. | 16.18 | - | - | - | - | - | - | - | - | - | - | - | - | |
Clinitech Laboratory Ltd. | 47.30 | - | - | - | - | - | - | - | - | - | - | - | - |
Vanta Bioscience Latest News
Vanta Bioscience Company background
Founded in: 2016
Managing director: Dopesh Raja Mulakala
Vanta Bioscience Limited was originally incorporated as a Private Limited Company on 29th April 2016 with the name Vanta Bioscience Private Limited. The Company converted into a Public Limited Company and the name was changed to Vanta Bioscience Limited on 17th March 2017.The Company is presently engaged in the business of Preclinical Activities. The Company provides risk assessment services for evaluating safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of product. The Company is established as a center of excellence for GLP toxicology and safety assessment offering services in India and across the globe. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms.The Company purchased preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as Vanta Bioscience (a toxicology division and commenced commercial activities in April, 2017. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives. In addition, the Company conducts preclinical proofofconcept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation. In September 2017, the Company came up with a Public Issue of 15,12,000 Equity Shares by raising money from public aggregating to Rs 7.56 Crore.In 201819, Vanta Clinical Research Limited and Vayam Research Solutions Limited became the subsidiaries of the Company.
Vanta Bioscience FAQs
How to buy Vanta Bioscience shares?
You can easily buy Vanta Bioscience shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
Please be aware that Vanta Bioscience stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account
